Vaccine efficacy of 80.6% for Bharat Biotech's Covaxin at the first interim analysis of phase-3 trials in India is indeed promising, though it took two months for the data to become available after the vaccine was approved for 'restricted emergency use' by the Indian drug regulator. The vaccine efficacy was measured based on symptomatic COVID-19 disease — mild, moderate or severe — two weeks after the second dose. The interim analysis undertaken at the first endpoint of 43 COVID-19 cases in the phase-3 trial carried out across 26 sites in India found 36 cases in the placebo group while only seven COVID-19 cases in the arm that received two doses of the vaccine given 28 days apart. The phase-3 trial that began last November recruited 25,800 participants, with one half receiving the vaccine and the other, a placebo. While the phase-3 trial will continue till 130 participants in both groups put together develop COVID-19 disease, another interim analysis will be carried out when there are 87 cases. Covaxin's efficacy of 80.6% at first interim analysis is higher than AstraZeneca/Covishield vaccine efficacy of 55.1% when the second dose is administered less than six weeks after the first; in India, the second dose of Covishield is approved for four-six weeks after the first. Also, the phase-3 trial recruited 2,433 participants over the age of 60 and included 4,500 people with comorbidities. However, those with severe and/or uncontrolled comorbidities were not recruited.
As per the phase-1 data published in The Lancet Infectious Diseases and a preprint of the phase-2 trial, Covaxin appears to be safe and highly immunogenic, and has also been found to be effective against the B.1.1.7 variant first found in Britain. While Covaxin accounts for less than 10% of all COVID-19 vaccinations in India, the absolute number of vaccinations as on March 3 stands at over 1.6 crore. No deaths associated with this vaccine have been reported so far. Though the first interim analysis is based on 43 cases, which is smaller when compared with other vaccines that have been approved by other regulators, the vaccine appears safe and efficacious in phase-3 and early stages of human trials and animal studies. The Indian regulator should therefore revise the restricted emergency use approval such that Covaxin is treated on a par with Covishield and should no longer seek additional precautions in the form of signed consent before vaccination and also remove the label "clinical trial mode" from the approval; their continuation would send a wrong signal about its safety and efficacy. With a narrow window of opportunity available to vaccinate people before a second wave probably sets in or dangerous variants get established, India can ill afford to have roadblocks in the uptake of either vaccine.
- What Should You Know About Milk Thistle Efficacy?
- Milk Thistle Efficacy and Liver Disease
- A Guide to Milk Thistle - Uses and Efficacy
- 3 Things Parents Need to Know About the Efficacy of Treatments For ADHD
- Ionic Air Purifier Review - Efficacy & Efficiency Tests
- ADHD Treatment Efficacy - What Criteria Can We Use?
- Studies on the Efficacy of Glucosamine For Arthritis
- Bird Flu Vaccine - Knowing Its Efficacy in Embattling the Avian Influenza Virus
- Street Fighting Moves - 2 Reasons Why Aerobic Efficacy is Not Paramount For Reality-Based Fighting
- Anti Aging Herbs Review and Their Efficacy
- Review of Best Female Libido Enhancing Herbs and Their Efficacy in Treating This Problem
- Combining Glucosamine and Chondroitin - Efficacy and Safety For Arthritis Sufferers
- Digital India: Tax officials express concerns over efficacy of faceless I-T assessment
- How To Tell If You Have Low Self Esteem and What to Do About it If You Do
- Self-Esteem - What is Self-Esteem and Why Do I Need Some? - Part 1
- Ionic Air Purifier Reviews - Reviewed
- The Body's Biggest Kept Secret About Detoxing the Liver
- Common Causes of Teeth Whitening Sensitivity
- Acai Berry on Oprah Winfrey Show - Did Oprah Lose Weight With the Acai Berry Diet?
- Operating Room Nurse Resumes
Efficacious too: On Covaxin have 636 words, post on www.thehindu.com at March 5, 2021. This is cached page on Asean News. If you want remove this page, please contact us.